

September 25, 2025



# Sonoma Pharmaceuticals to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

**BOULDER, COLORADO / [ACCESS Newswire](#) / September 25, 2025** / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, and animal health care, today announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025.

## Company Webcast

The webcast presentation will take place at 2:00 p.m. ET on Tuesday, September 30, 2025. The webcast can be accessed by visiting the conference home page at <https://lythampartners.com/fall2025/> or directly at <https://app.webinar.net/A3L8zpab2q9>. The webcast will also be available for replay following the event.

## 1x1 Meetings

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at [1x1@lythampartners.com](mailto:1x1@lythampartners.com) or register for the event at <https://lythampartners.com/fall2025invreg/>.

## About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in over 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at [www.sonomapharma.com](http://www.sonomapharma.com). For partnership opportunities, please contact [busdev@sonomapharma.com](mailto:busdev@sonomapharma.com).

## Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "opportunities," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.

Sonoma Pharmaceuticals™ and Microcyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.

**Media and Investor Contact:**

Sonoma Pharmaceuticals, Inc.  
[ir@sonomapharma.com](mailto:ir@sonomapharma.com)

Website: [www.sonomapharma.com](http://www.sonomapharma.com)

Follow us on LinkedIn: <https://www.linkedin.com/company/sonoma-pharmaceuticals>

Follow us on Instagram: [https://www.instagram.com/sonomapharma\\_us/](https://www.instagram.com/sonomapharma_us/)

Follow us on Facebook: <https://www.facebook.com/sonomapharma/>

**SOURCE:** Sonoma Pharmaceuticals, Inc.

View the original [press release](#) on ACCESS Newswire